EndoStim is a medical device company developing therapeutics for gastrointestinal and urological neuro-muscular disorders.
EndoStim is a medical device company developing therapeutics for gastrointestinal and urological neuro-muscular disorders. It is performing clinical trials to pursue FDA approval for a new treatment for sphincter-related disorders such as gastroesophageal reflux disease (GERD) and urinary urge incontinence. Its microstimulator technology provides long-term reflux control by restoring normal esophageal function that directly targets the patient's weak or dysfunctional lower esophageal sphincter (LES) muscle between the stomach and the esophagus and enable patients to reduce or avoid typical gastrointestinal side effects of traditional anti-reflux surgery.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 16, 2018 | Series E | $12.14M | — | — | — | Detail |
May 12, 2016 | Series D | $25M | 4 | Endeavour Vision Sante Ventures | — | Detail |
Jul 10, 2014 | Debt Financing | $6.36M | — | — | — | Detail |
Jun 5, 2013 | Series D | $14.10M | 3 | — | — | Detail |
Jan 14, 2013 | Series C | $9.13M | 3 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Endeavour Vision | Yes | Series D |
Sante Ventures | Yes | Series D |
Gimv | — | Series D |
Wellington Partners | — | Series D |
Vectis Healthcare & Life Sciences Fund II | — | Series D |
Prolog Ventures | — | Series D |
Billiken Angels Network | — | Series C |
Vectis Healthcare & Life Sciences Fund | — | Series B |